• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Adherence to Action Plan for COPD Exacerbations Reduces Recovery Time

Article

Patients who followed a written action plan for exacerbations of chronic obstructive pulmonary disease (COPD) had shorter recovery times, reported Canadian researchers.

Patients who followed a written action plan for exacerbations of chronic obstructive pulmonary disease (COPD) had shorter recovery times, reported Canadian researchers.

The 1-year prospective cohort study included 252 patients with COPD who were given a written action plan for prompt treatment of exacerbations. Patients were instructed to fill standing prescriptions for both antibiotics and prednisone within 3 days of the onset of an exacerbation.

In about 40% of exacerbations, patients adhered to the plan. Adherence reduced exacerbation recovery time by 5.8 days (P = .0001); however, it had no significant effect on unscheduled use of healthcare resources.

The researchers found that patients who were most likely to adhere to an action plan had been vaccinated against influenza, had a cardiac comorbidity, were younger, or had a lower FEV1 as percentage of predicted.

 

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Infectious disease specialist talks about COVID-19 vaccine development
© 2024 MJH Life Sciences

All rights reserved.